

MCPHERSON'S

Est. 1860

MCPHERSON'S LIMITED

AGM 2020

4TH NOVEMBER 2020

DRLEWINN'S*







swisspers^{*}

Multix



GRAHAM CUBBIN, CHAIRMAN





OUR **BOARD**

OUR BOARD'S EXPERIENCE REFLECTS OUR STRATEGY



GRAHAM A. CUBBIN
Independent Non-Executive
Director



GEOFFREY R. PEARCE
Non-Independent
Non-Executive Director



JANE M. MCKELLAR
Independent Non-Executive
Director



ALISON J. MEW
Independent Non-Executive
Director



GRANT W. PECK
Independent Non-Executive
Director




CEO & Managing
Director

ONLINE ATTENDEES - VOTING PROCESS

 When the poll is open, the vote will be accessible by selecting the voting icon at the top of the screen




- To vote simply select the direction in which you would like to cast your vote, the selected option will change colour.
- There is no submit or send button, your selection is automatically recorded.



ONLINE ATTENDEES – QUESTION PROCESS

 When the Question function is available, the Q&A icon will appear at the top of the app.

- To send in a question, simply click in the 'Ask a question' box, type your question and the press the send arrow
- Your question will be sent immediately for review





PEOPLE First

"During the COVID-19 pandemic the ongoing well-

being and support of our employees as they work

in challenging circumstances has been, and

continues to be, our highest priority"

FY20 KEY FINANCIAL highlights

- Sales from owned brand, + 16% on FY19
- Underlying profit before tax, +20% on FY19
- Underlying operating cash conversion of 103%
- Investment in our R&D capability, + 33% headcount
- Sales to ABM, + 133% on FY19
- Net bank debt, excluding lease liabilities, very low at \$9.2 million

RECENT Developments

- Strong start to FY21
- Significant non-recurring provision for hand sanitiser
- Acquisition of Global Therapeutics the first serious move into Health
- Capital raise via \$36.5m institutional placement & share purchase plan

LAURIE MCALLISTER, CEO AND MANAGING DIRECTOR



OUR MANAGEMENT **TEAM**



SARAH TULLY HR Director



PAUL WITHERIDGE
Chief Financial Officer



DONNA CHANMarketing Director



DAVID FIELDING
Strategy, Planning and
Innovation Director



LORI PIROZZI
International Sales
Director



BRETT OWERS
Commercial and M&A
Director



MARY PEARCE R&D Director



MARK BRADY
Supply Chain Director



LAURENCE MCALLISTER
CEO & Managing Director

HEALTH, WELLNESS & BEAUTY - A \$17





HEALTH
(\$4.9 BILLION, +3.9% VS YA)

The intent of enhancing and restoring health via symptomatic treatment

WELLNESS
(\$5.7 BILLION, +3.8% VS YA)

Maintain the state of good health by pro-actively seeking to prevent the onset or worsening of conditions

BEAUTY (\$6.5 BILLION, **+2.8**% VS YA)

The subjective enhancement of physical perception for ones own satisfaction

FY2020 STRATEGIC BUSINESS IMPERATIVES

- REFOCUS MCPHERSON'S ON HEALTH, WELLNESS & BEAUTY WITH SUSTAINABILITY AND PEOPLE AT THE CORE
- REVITALISE OUR OWN MCPHERSON'S BRANDS
- ENSURE A **HEALTHY BALANCE** SHEET
- MOVE FROM TRANSACTIONAL TO STRATEGIC PARTNERSHIPS WITH OUR TOP SIX CUSTOMERS
- INTEGRATE AND GROW ACQUIRED SKINCARE BRANDS; DR. LEWINN'S AND A'KIN


- 6 CREATE A CHINA FACING BUSINESS
- ENSURE WE HAVE OUR TEAM FIT FOR THE FUTURE WITH APPROPRIATE EXPERTISE, CAPABILITIES AND VALUES
- STABILIZE AND GROW NZ & SINGAPORE AND EXPAND IN ASIA & INTERNATIONAL
- GAIN EFFICIENCIES AND SAVINGS ACROSS SUPPLY CHAIN INFRASTRUCTURE
- CREATE A **NEW BUSINESS TEAM** FOCUSED ON SIGNIFICANT M&A OPPORTUNITIES

FY2021 STRATEGIC BUSINESS IMPERATIVES

- CONTINUE TO PROTECT & GROW THE MCPHERSON'S CORE 5 HW&B BRANDS IN LINE WITH KEY MACRO TRENDS
- TURBO CHARGE DR. LEWINN'S GLOBAL GROWTH PLAN ACCELERATE NPD PIPELINE & NEW GEOGRAPHIES
- ACCELERATE ABM GREATER CHINA JV STRATEGY & CAPABILITIES INNOVATION CYCLE, SUPPLY CHAIN, NEW BRANDS & CATEGORY EXPANSION
- PARTNER WITH CUSTOMERS TO DRIVE BRAND,
 CATEGORY & CHANNEL EXPANSION THROUGH SUPERIOR
 INSTORE AND ONLINE CONSUMER EXPERIENCE
- CONTINUED INVESTMENT IN OUR PEOPLE DEVELOPMENT, CAPABILITIES & CULTURE WITHIN AN EVER-CHANGING ENVIRONMENT

- EXPEDITE HW&B PORTFOLIO EXPANSION THROUGH INCREASED R&D PARTNERSHIPS & NPD INVESTMENT
- ACCELERATE OUR SUSTAINABILITY AGENDA. ENGAGING PEOPLE & COMMUNITIES, THE PLANET, OUR PORTFOLIO & PARTNERS
- UTILISE STRONG BALANCE SHEET AND EXCESS
 CAPACITY TO LAND MEANINGFUL M&A AND GEOGRAPHIC
 EXPANSION FOCUSING ON USA, EU & ASIA
- REJUVENATE NEW ZEALAND & SINGAPORE REGIONS TO DELIVER BUDGETED (+) EBIT TARGETS
- DELIVER TARGETED COST SAVING INITIATIVES

PEOPLE FUSE



DURING COVID-19, THE
WELLBEING AND SUPPORT OF
OUR EMPLOYEES AS THEY
WORK IN CHALLENGING
CIRCUMSTANCES CONTINUES
TO BE OUR HIGHEST PRIORITY.

Despite COVID-19, within Australia, we have:

- Been consistent in paying full corporate taxes
- Employed additional staff, continuing to grow our business and people
- Received no job keeper/seeker assistance

MCPHERSON'S FINANCIAL HIGHLIGHTS AND CAPITAL RAISE SUMMARY



COMMENTARY ON Q1 FY21 FINANCIAL OUTCOME

- ➤ 4% growth in sales revenue to \$49.7 million
- > 8% growth in sales revenue from owned brands to \$41.7 million
- ➤ 84% growth in underlying PBT to \$2.9 million
- Growth in category market share in 4 out of 6 core brands
- Continued strong China sales trajectory fuelled by ABM partnership model
- \$5.7 million non-recurring full provision for write-down of hand sanitiser inventory
- Forecast growth in first half FY21 underlying profit before tax in the range of 20% to 30% above FY20 and forecast growth in full year FY21 profit before tax in the range of 5% to 10% above FY20
- Dividend policy remains unchanged and will be applied to underlying profit after tax




CAPITAL RAISE SUMMARY

- ⇒ \$36.5m institutional placement completed on 28 October 2020 at \$2.27 per share representing 15% of pre-raise issued capital
- A Share Purchase Plan (SPP) is being offered to eligible shareholders in Australia and New Zealand to raise up to \$10 million
- > SPP to be priced at the lower of (i) \$2.27 per share or (ii) a 2.5% discount to the volume-weighted average price over the five trading days up to and including the SPP closing date (expected to be 20 November 2020)
- Results of SPP expected to be published on 25 November 2020
- SPP shares expected to be issued on 27 November 2020
- Proceeds from the institutional placement & SPP to be applied to:
 - fund the acquisition of Global Therapeutics and transaction costs; and
 - provide McPherson's with additional balance sheet capacity for potential future acquisition and growth initiatives.





INNOVATION SUCCESS FUELLING SUSTAINABLE GROWTH





MP



AUSTRALIA & EXPORT CHINA NPD



#1 HAIR BRUSH NPD PHARMACY



#1 NATURAL HAIRCARE NPD



FIRST TO MARKET LASH NPD

220 PROJECTS IN THE INNOVATION FUNNEL

FY20: COVID RESILIENT OWNED BRAND PORTFOLIO









DC





BRAND PORTFOLIO WELL POSITIONED AGAINST MACRO TRENDS



GLOBAL EXPANSION

- Global Health Wellness & Beauty estimated to be worth \$4.5T with Beauty contributing \$1T.
- China is the world's second largest Beauty market and expected to grow to \$52B by 2025.



PROACTIVE BEAUTY

- Custodians of your own skin health. More choice, technology, information & education enabling empowerment.
- 33% of women say they have added beauty supplements to their skincare routine in the last year (DRL opportunity).



SUSTAINABLE SOLUTIONS

- 87% of Shoppers are more likely to purchase products that are ethically and sustainably produced.
- 41% of shoppers are willing to pay more for ethical and sustainable products.



NEW COVID NORM

- 50% of Australians do not expect life to return to normal for at least 6 months.
- 46% Australians working from home.
- Baking ranked #2 to bring joy or reduce stress during COVID.

DR LEWINN'S®

A'kin

swisspers*

DR.Lewinn's®







swisspers[®]







FY21: LEVERAGE MACRO TRENDS TO DRIVE FUTURE GROWTH



GLOBAL EXPANSION



PROACTIVE BEAUTY











CATEGORY EXPANSION Clinically Proven Inside Out Beauty



RANGE EXPANSION Scientifically Proven Haircare

Continue market expansion plans to build new hero's

FY21: LEVERAGE MACRO TRENDS TO DRIVE FUTURE GROWTH



SUSTAINABLE SOLUTIONS



NEW COVID NORM

























FIRST TO MARKET

Compostable, Biodegradable & Resealable

INCREASED GREENER USAGE

ECO EXPANSION Cotton Tips Paper Stem across all pack sizes

Upsize for larger households Glam Cam Lash App

MCPHERSON'S CHANNEL & CUSTOMER



MCP PERFORMANCE FY20 IN TRADITIONAL Channels





4 OUT OF 6 CORE BRAND ACCELERATING AHEAD OF CATEGORY GROWTH



FASTEST GROWING TOP 5 AUSTRALIAN SKINCARE SUPPLIER AT 19.5% DR. LEWINN'S SHELF PRESENCE INCREASE +33% IN PRICELINE +25% CHEMIST WAREHOUSE



MCP SWISSPERS GROWTH X 1.6 AHEAD OF GROCERY COTTON CATEGORY PORTFOLIO MANAGEMENT DRIVING PROFITABILITY IN GROCERY CHANNEL

FY20 DEMONSTRATED AGILITY AND RESILIENCE

CONTINUED FOCUS ON EXECUTION







PIVOT TO ONLINE RETAIL

NEW CUSTOMERS

OZ HAIR & BEAUTY

INCREMENTAL RANGING

+ 112

PRODUCTS ONBOARDED WITH ONLINE RETAILERS

INVESTMENT

+ 30%

INVESTMENT TO CUSTOMER ONLINE PLATFORMS

CHANNEL EXPANSION

CHANNEL PENETRATION



WOOLWORTHS B2B

CORE RANGE DISTRIBUTION

+ 10%

INCREASE IN COMPLIANCE INDEPENDENT CHANNELS

A'KIN IN GROCERY



+5000

Foodstuffs (12)

DISRTIBUTION POINTS ACCEPTED

MACRO RETAIL TRENDS SHAPING MCP SALES Grategy





CHANNEL SHIFT

- Annual E-commerce spend \$25B in June 2020 +31.9% vs YA
- 84% of Australians engaging in online shopping
- During COVID shift in skincare spend from Pharmacy to Grocery



GLOBALISATION

- 64.8% of Top 250 retailers have foreign operations
- Online facilitating expansion
- Global Expansion of AU retailers in B&M and Online



DIFFERENTIATION

- Over 120 Exclusive/Pseudo brands available within categories MCP participates in
- 58% of people are now considering private label
- Retailer strategies continue with Exclusives key pillar



SHOPPER ENGAGEMENT

- 53% of shoppers are likely to change their minds based on what they see in store
- Retailers partnering with suppliers offering navigation and Category solutions

MACRO RETAIL TRENDS SHAPING MCP SALES Avategy







- Greater online presence
- Pivot Investment
- **Channel Expansion**



GLOBALISATION

- Strategic partnerships
- Participation In Expansion
- **Execution of Integrated Global Plans**




DIFFERENTIATION

- **Exclusive products**
- First to markets
- Strategic play in Private Label and Pseudo brands



SHOPPER ENGAGEMENT

- Integrated online/instore
- Off location investment
- Category & Navigation solutions









ANZ OPERATIONAL SALES IMPERATIVES





RANGE AND INVESTMENT OPTIMISATION



EXECUTION & INNOVATION



EXPANSION

PIVOT INVESTMENT & PRESENCE ONLINE

CONTINUED PORTFOLIO MANAGEMENT

PROMOTIONAL EFFECTIVENESS

RESHAPE TRADING TERMS FOR GROWTH OUTCOMES

RETAILER EXCLUSIVES

GROWTH FROM CORE AND INNOVATION

CATEGORY AND NAVIGATION SOLUTIONS

STRATEGIC PARTICIPATION IN PRIVATE LABEL

NEW CHANNEL PENETRATION

CORE DISTRIBUTION EXPANSION

GEOGRAPHIC EXPANSION

NEW CATEGORY ENTRY INTO HEALTH

GLOBAL THERAPEUTICS



COMPANY OVERVIEW

Global Therapeutics develops, markets and sells Traditional/Oriental & Western herbal complementary medicine formulations in Australia and New Zealand

BACKGROUND

- Leader in combining traditional herbal & western complementary medicines
- Focused on embedding traditional herbal medicine evidence and principles with modern dosage and sciencebased materials
- Strong brand heritage supported by highly qualified and aligned management team
- Deep Health Food & growing pharmacy distribution channels with loyal consumer following

HISTORY	
1999	 Global Therapeutics established Oriental Botanicals launched into the practitioner market
2001	 Fusion Health launched into HFS channel
2012	Oriental Botanicals launched into pharmacies
2016	 Global Therapeutics acquired by Blackmores
2020	McPherson's acquires Global Therapeutics



EXECUTING MCPHERSON'S STRATEGY


GLOBAL THERAPEUTICS DELIVERS ON MCPHERSON'S STRATEGY OF BUILDING A STRONG HEALTH AND WELLNESS PILLAR FOCUSED ON OWNED BRANDS AND PRODUCTS, WITH SIGNIFICANT GROWTH AND MARKET SHARE POTENTIAL RELATIVE TO THE BROADER CATEGORY




NOTES: BRANDS AND PRODUCTS ABOVE CATEGORISED AS PER PREVIOUS ASX DISCLOSURES

REVENUE SEGMENTATION

Diversified, premium product portfolio focused on large sub-segments within the supplements market including immunity, muscular support, bone and joint health, digestive and women's health





DF

DISTRIBUTION NETWORK

Highly complementary distribution network including pharmacy and specialty health food stores. Opportunity to leverage McPherson's expanding online and export sales channel








GLOBAL THERAPEUTICS' MARKET POSITIONING

HERBAL AND TRADITIONAL PRODUCTS ARE A NICHE HIGH GROWTH SUB SEGMENT OF THE BROADER COMPLEMENTARY MEDICINES SECTOR

HERBAL / TRADITIONAL PRODUCTS IS A NICHE, HIGH GROWTH SUB SEGMENT OF COMPLEMENTARY MEDICINES WHICH IS CHARACTERIZED BY HIGHER MARGIN PRODUCTS



AUSTRALIAN COMPLEMENTARY MEDICINES

T10% 2014/2019 CAGR HERBAL & TRADITIONAL **PRODUCTS**

2014/2019

78%

Of Australians have purchased at least one form of complementary medicine in the last year 83%

Of Australian women have purchased at least one form of complementary medicine in the last year

1 of 3



Australians using **Complementary Medicines** to manage symptoms of chronic disease

Export



Australian complementary medicines are recognised around the world for quality, safety and efficacy

SOURCE: COMPLIMENTARY MEDICINES AUSTRALIA: INDUSTRY AUDIT & TRENDS 2020

A WINNING INTEGRATION STRATEGY

GLOBAL THERAPEUTICS REPRESENTS A TRANSFORMATIONAL AND STRATEGICALLY COMPELLING ACQUISITION, WITH SIGNIFICANT GROWTH OPPORTUNITIES, THAT ADVANCES MCPHERSON'S POSITION IN HEALTH AND WELLBEING



DELIVERS ON
STRATEGIC IMPERATIVE
TO ENTER HEALTH AND
WELLNESS CATEGORY A NEW GROWTH
PLATFORM

- ESTABLISHES A HEALTH & WELLNESS BUSINESS FOR MCPHERSON'S THAT IS EPS ACCRETIVE
- RECOGNISED AND RESPECTED BRANDS PROVIDING UNIQUE POINTS OF DIFFERENCE
- STRONG MARGIN AND HIGH VALUE PRODUCTS
- EXPANDS CHANNEL DIVERSITY FOR MCPHERSON'S AND PROVIDES ENTRY INTO NEW CATEGORIES
- HIGH QUALITY TEAM WITH DEEP INDUSTRY KNOWLEDGE TRANSITIONING WITH BUSINESS TO EXECUTE HEALTH & WELLNESS
 STRATEGY
- PROVIDES A DIVERSIFIED SET OF TGA-LICENSED CONTRACT MANUFACTURING PARTNERSHIPS

A WINNING INTEGRATION STRATEGY (CONT)



ABILITY TO LEVERAGE
ACROSS PLATFORMS
AND GENERATE
OPERATING
EFFICIENCIES

- LEVERAGE MCPHERSON'S AVAILABLE KINGSGROVE WAREHOUSE CAPACITY (40% CAPACITY AVAILABLE)
- COLLABORATION BETWEEN HIGH QUALITY SALES & MARKETING TEAMS
- POTENTIAL MEDIUM TERM EFFICIENCIES. LEVERAGE NEW TECHNICAL CAPABILITIES ACROSS THE EXISTING MCPHERSON'S PORTFOLIO (EG. DIGESTIBLE BEAUTY SUPPLEMENTS)
- GLOBAL THERAPEUTICS DISTRIBUTION CHANNELS TO BENEFIT MCPHERSON'S EXISTING HEALTH BRANDS



- SCOPE TO INCREASE RESOURCES ALLOCATED TO NEW PRODUCT DEVELOPMENT TO ACCELERATE INNOVATION AND GROW
 ADDRESSABLE MARKET
- GROWTH OPPORTUNITIES IDENTIFIED WITHIN NEW ZEALAND
- FUTURE INTERNATIONAL EXPANSION OPPORTUNITIES INCLUDING CHINA AND OTHER ASIAN MARKETS
- BYRON BAY PROVENANCE AND HERITAGE FURTHER ENHANCED

PRO FORMA FINANCIAL IMPACT

GLOBAL THERAPEUTICS HAS STRONG MARGINS PROVIDING SCOPE FOR MCPHERSON'S TO GROW THE BUSINESS. THE ACQUISITION FURTHER DIVERSIFIES MCPHERSON'S SALES MIX AND INCREASES REVENUE DERIVED FROM OWNED BRANDS (~85% FY20 PRO FORMA REVENUE)


PERIOD ENDING 30 JUNE 2020 ASM	AUDITED MCP (FY20)	UNAUDITED GLOBAL THERAPEUTICS (FY20)	UNAUDITED PRO FORMA COMBINED (FY20)	
Revenue ¹	222.2	19.5	241.6	
Underlying EBIT ²	25.1	3.7 ³	28.8	
Key Statistics				
Revenue growth	5.6%	-7.3%	4.5%	
Underlying EBIT growth ¹	17.3%	19.9%	17.6%	
Underlying EBIT margin¹	11.3%	18.8%	11.9%	

Strong margins

Providing scope for McPherson's to invest to grow the business

Incremental sales and earnings growth

Whilst maintaining a prudent capital structure



EPS Accretive

Acquisition is expected to be mid single digit EPS accretive on a pro forma FY21 basis before expected transaction costs and synergies⁴

Meaningful

Revenue and operational synergies identified over medium term

NOTES:

1. REVENUE IS RECOGNISED AS GROSS SALES NET OF DISCOUNTS AND REBATES. 2. UNDERLYING EBIT INCLUDING WAREHOUSING AND IDENTIFIED

ADDITIONAL REGULATORY AND SUPPORT RESOLUTION FACILITY PAISON AND THE ACQUISITION WAS COMPLETED ON A JULY 2020 AND INCLUDING THE PROPORTION OF FOURTY PAISON APPROPRIES.

MCPHERSON'S FY 2020 **EXPORT** RESULTS HIGHLIGHTS




ACCESS CORPORATE GROUP

Livia Wang

Chief Brand Officer

ACG 2018-2020 GMV GROWTH (A\$M)





OUR FACTS

We connect

Our owned and invested brands operate

stores worldwide

Our logistics network covers

25 countries

In a single year we ship

1,500 containers of products

VTN app social engagements

100 million

We engage 5,000 +

Taobao sellers, Little Redbook KOLs, and individual retail store owners


Together with 50,000 resellers worldwide, we serve $10\ million$ consumers across the globe

ACCESS & DR. LEWINN'S

Growth Partnership | Integrated NPD Marketing STRATEGY Global **Smart Supply** Expansion Chain

SALES GROWTH
by Campaign (GMV in RMB)

Access Corporate Group



DOUBLE 6 PERFORMANCE - DR. LEWINN'S

Access Corporate Group

We served

100,000+ consumers across the globe

We delivered Dr. LeWinn's products to

9+ countries 879+

Triple Action Defence SOLD

85,000 units



High Potency Treatment Mask SOLD

66,000 units



Ultra R4 Collagen Surge Plumping Gel SOLD

60,000 units



HA Eye Mask SOLD



Ageless Trinity Pack SOLD

21,000 units



HA Boosting Essence SOLD



AWARDS + RECOGNITIONS



WINNER Prevention Magazine Beauty Innovation Award





PRODUCT - Line Smoothing Complex Triple Action Day Defence







PRODUCTS – Clinically proven, tried and tested.



MASKING

BAZAAR

marie claire

2020嘉人百大赏面霜类

专家+编辑推荐奖

DELEWINNS







Women's Weekly

starters, the word "acid" doesn't conjure a pretty picture, does it? But stay with onnective tissue. It acts as cushioning agent, and the reason it's so buzzed abou





Dr Lewinn's Line Smoothing Complex S8 High Potency Treatment Mask Pack

If you're face is feeling crepey, tight, or flaky, a concentrated dose of hyaluronic acid will work wonders. This sheet mask will do just that, plus it's also soupedup with green tea and peptides to reduce the appearance of fine lines. While it's perfect for special occasions, the price tag means you can afford to indulge





「R4胶原蛋白小粉珠」 「三色凝胶」 莱文医生R4活颜紧致系列胶原蛋白凝珠

菜文医生八粒肽三重赋活日间凝胶

DRLEWINN'S"

CHINA INTERNATIONAL IMPORT EXPO SHANGHAI, 5TH~10TH NOVEMBER

The Gateway to the huge Chinese market, rapid growth of consumption and import

150,000+ global professional purchasers

Participants from 100+ countries

\$10 Trillion potential import market in the future



DOUBLE 11 FORECAST

TARGET RMB GMV

154 Million

BRAND DAY 4th November















THANK YOU

Everyday better life


Gear on Gear

FY17 \$500K 1 HERO PRODUCT FY18 \$3.1M +529% 2 HERO PRODUCTS FY19 \$16M +413% 3 HERO PRODUCTS FY20 \$37M +133% 5 HERO PRODUCTS FY21 \$48M +30% 6 HERO PRODUCTS

Top Performer in China



DR. LEWINN'S RETAINS A TOP 3 POSITION IN THE ABM PORTFOLIO



WECHAT SEARCH
HISTORY SHOWS
BUILDING
AWARENESS IN
CHINA

SKU MIX IS DE-RISKED AS HERO PRODUCT SCOPE GROWS STRONGER















NEW PRODUCT INNOVATION

- LED BY CHINA INSIGHTS
- EXPANDING INTO NEW FORMATS
- DRIVING GROWTH THROUGH INNOVATION









IN MAY 2020 AWARE PRODUCED THE 1 MILLIONTH UNIT OF DR. LEWINN'S IN FY20 MCP PROGRESSIVELY
INCREASED THEIR EQUITY
STAKE IN THE AWARE GROUP
TO 10%

AWARE MANUFACTURES OVER 25% OF ALL DR. LEWINN'S PRODUCTS OVER 50 SKUS
HAVE SUCCESSFULLY
UNDERGONE A TECH
TRANSFER



A'KIN Natural Australian Skincare MCPHERSON'S S Akin Alustralian skincare OUTLOOK ATURAL AUSTRALIAN SKINCARE AGE-DEFY LINE SMOOTHING DAY CREAM LIFTING EYE CREAM ALL SKIN TYPES] @15mL/0.5FLOZ.US NATURAL AUSTRALIAN SKINCARE FIRMING NIGHT CREAM

CURRENT TRADING & OUTLOOK FOR FY21

- FOLLOWING +20% IN FY20 UNDERLYING PBT, Q1 UNDERLYING PBT +84%
- CORE BRANDS +8% ON PCP
- DR. LEWINN'S Q1 +19% IN EXPORT CHANNEL
- STRONG UNDERLYING TRADING AND FINANCIAL POSITION DESPITE NON-RECURRING PROVISION FOR EXCESS HAND SANITISER
- GROWTH THROUGH M&A IS A STRATEGIC PRIORITY GLOBAL THERAPEUTICS FIRST INITIATIVE TO ESTABLISH A NEW HEALTH DIVISION AT MCPHERSON'S
- EXTREMELY HEALTHY BALANCE SHEET / LOW GEARING (9%), DIVIDEND INTENT TO APPLY A MINIMUM 60% OF UNDERLYING PROFIT AFTER TAX
- MANAGEMENT GUIDANCE OF +5 TO +10% UNDERLYING PBT VS PRIOR YEAR



PEOPLE First



THE ONGOING WELLBEING AND SUPPORT OF OUR EMPLOYEES CONTINUES TO BE OUR HIGHEST PRIORITY



AGENDA ITEM 1 – FINANCIAL STATEMENTS / OTHER REPORTS

TO CONSIDER THE FINANCIAL STATEMENTS AND REPORTS FOR Y/E 30 JUNE 2020

SHAREHOLDERS ARE NOT REQUIRED TO VOTE OR FORMALLY APPROVE OR ADOPT THE FINANCIAL REPORTS.

SHAREHOLDERS CAN, HOWEVER, SUBMIT QUESTIONS REGARDING THE FINANCIAL REPORTS AND THE COMPANY

AGENDA ITEM 2 - REMUNERATION REPORT

TO ADOPT THE REMUNERATION REPORT FOR THE FINANCIAL YEAR ENDED 30 JUNE 2020

IN ACCORDANCE WITH THE CORPORATIONS ACT 2001 (CTH) (CORPORATIONS ACT), THIS RESOLUTION IS ADVISORY ONLY AND DOES NOT BIND THE COMPANY OR THE DIRECTORS OF THE COMPANY. THE DIRECTORS WILL CONSIDER THE OUTCOME OF THE VOTE AND COMMENTS MADE BY SHAREHOLDERS ON THE REMUNERATION REPORT AT THE MEETING WHEN REVIEWING THE COMPANY'S REMUNERATION POLICIES.

AGENDA ITEM 3 — RE-ELECTION OF A DIRECTOR — MS. JANE MCKELLAR



TO PASS THE FOLLOWING RESOLUTION AS AN ORDINARY RESOLUTION:

"TO RE-ELECT, AS A DIRECTOR OF THE COMPANY, MS. JANE MCKELLAR, WHO RETIRES BY ROTATION AS A DIRECTOR IN ACCORDANCE WITH THE COMPANY'S CONSTITUTION AND THE ASX LISTING RULES AND OFFERS HERSELF FOR RE-ELECTION."

AGENDA ITEM 4 - AMENDMENT OF CONSTITUTION

TO CONSIDER AND, IF THOUGHT FIT, TO PASS THE FOLLOWING RESOLUTION AS A SPECIAL RESOLUTION:

"THAT, FOR THE PURPOSES OF SECTION 136(2) OF THE CORPORATIONS ACT, THE COMPANY'S CONSTITUTION IS AMENDED BY THE INCLUSION OF THOSE PROVISIONS SET OUT IN THE EXPLANATORY NOTES TO THIS NOTICE OF ANNUAL GENERAL MEETING WHICH REFER TO THIS RESOLUTION."

RESOLUTIONS - PROXY VOTES

		PROXY VOTES RECEIVED (MILLIONS)							
	RESOLUTION	FOR NO.	FOR %	AGAINST NO.	AGAINST %	OPEN NO.	OPEN %		
2	REMUNERATION REPORT	57.5	97.3%	0.9	1.6%	0.7	1.1%		
3	RE-ELECT JANE MCKELLAR	58.4	98.9%	0.0	0.1%	0.6	1.0%		
4	4 AMEND CONSTITUTION	58.1	98.3%	0.3	0.6%	0.7	1.1%		



